By Bethany McLean, includes “By 2015, C.E.O. Michael Pearson had built Valeant Pharmaceuticals into a nearly $90 billion colossus. Today, the company is under investigation for price gouging, and major Wall Street players are feeling the side effects. Pearson’s fall (which came with a $9 million severance package last week), exposes more than the dark side of the health-care system—it indicts some of finance’s biggest players…”
Read the full article on: Vanity Fair